Australian researchers claim that a new generation of vaccines will protect people from getting the virus into the body.
Australian researchers have begun clinical trials of a new type of vaccine against COVID-19, which will be administered using a nasal spray. Scientists from the Brisbane-based Nuclear Network suggest that the new vaccine may be more effective in comparison with drugs from AstraZeneca and Pfizer. In addition, many people who are afraid of injecting needles will then be able to decide to get vaccinated.
So far, Australia’s vaccination program has been slow compared to other countries. Among the reasons are supply problems, a lack of planning on the part of government agencies, and the indecision of Australians themselves, “reassured” by the relatively low level of coronavirus infection in the country.
Dr. Paul Griffin, medical director of the Nucleus Network, a research organization that is beginning trials of a new type of vaccine in the form of a nasal spray, says that while existing vaccines mostly protect people from COVID-19 complications, the Australian drug aims to reduce the risk of infection.
“The main advantage is that when we introduce a vaccine in the same way that a pathogen or virus enters the body, it increases the effectiveness… and, we hope, actually prevents the virus from entering,” Griffin said.
The Independent Ethics Committee approved the start of the research. Scientists say that the vaccine in the form of a nasal spray will be available to patients in about a couple of years.
Two COVID-19 vaccines – AstraZeneca and Pfizer – have now been approved for use in Australia. The country’s public health authorities said this week that the AstraZeneca drug will now be recommended for use by people aged 60 and over. This is associated with a fairly rare risk of developing thrombosis in young people.
The authorities plan to complete the vaccination by the end of 2021. To date, about 30 thousand cases of coronavirus infection have been registered in Australia, which has killed more than 900 people.